|
Re: RVX Announces Update Webcast and Conference Call
|
4
|
Resverlogix Corp.
|
Jan 19, 2021 08:43PM
|
|
Re: RVX Announces Update Webcast and Conference Call
|
2
|
Resverlogix Corp.
|
Jan 18, 2021 08:55AM
|
|
Re: RVX Announces Update Webcast and Conference Call
|
2
|
Resverlogix Corp.
|
Jan 18, 2021 09:28AM
|
|
Re: Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
|
5
|
Resverlogix Corp.
|
Apr 27, 2021 05:16PM
|
|
Re: Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
|
5
|
Resverlogix Corp.
|
Apr 27, 2021 03:21PM
|
|
Re: Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
|
4
|
Resverlogix Corp.
|
Apr 27, 2021 03:48PM
|
|
Re: Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
4
|
Resverlogix Corp.
|
Jan 27, 2021 07:37PM
|
|
Re: Resverlogix announces HEPALINK debenture $6mill
|
1
|
Resverlogix Corp.
|
May 05, 2021 10:19AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 05:42PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 08:02AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 08:13AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 08:59AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 11:10AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 04:26PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 04:45PM
|
|
Re: Rant time...
|
|
Resverlogix Corp.
|
Feb 05, 2021 11:35AM
|
|
Re: Rant time...
|
|
Resverlogix Corp.
|
Feb 05, 2021 12:43PM
|
|
Re: Quote from a January 19, 2021 review
|
1
|
Resverlogix Corp.
|
Jan 21, 2021 04:45PM
|
|
Re: Price
|
3
|
Resverlogix Corp.
|
Dec 31, 2020 11:23AM
|
|
Re: Presentation is gone
|
2
|
Resverlogix Corp.
|
May 14, 2021 10:01AM
|
